Adam Feuerstein

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

 


Feuerstein graduated from Emory University with a bachelor's degree in political science.

 


Recent Articles By The Author

Acceleron, Celgene Seek to Replace Entrenched Anti-Anemia Drugs in MDS Treatment

While a phase III study progresses, Acceleron is searching for different populations of MDS patients where luspatercept might also be effective.

Human Blood Substitutes, Once Dead, Now Resuscitated

Human Blood Substitutes, Once Dead, Now Resuscitated

A nanotechnology derived artificial red blood cell could be used in life-saving situations like trauma accidents or the battlefield where donated blood is unavailable.

Spark's Hemophilia Gene Therapy Remains Effective Despite Immune Reactions

Spark's Hemophilia Gene Therapy Remains Effective Despite Immune Reactions

Spark believes temporary treatment with steroids can arrest the immune response before it causes factor IX levels to fall to a point where bleeding risk becomes a problem.

Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects

Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects

'We're seeing impressive, early responses with BB2121 without the toxicity,' says Bluebird CEO Nick Leschly.

Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield

Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.